UNSPSC 51432303: Moxonidine

This classification denotes an antihypertensive agent with the molecular formula C9H12ClN5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CC6X0L40GW, chemically known as 5-pyrimidinamine, 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl- (9ci) but generally known as moxonidine, which bears US NIH Compound Identifier 4810. European Medicines Agency schedules Moxonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09092MIG. The term MOXONIDINE is an International Non-Proprietary Name.

UNSPSC 51432303 Moxonidine, a Commodity code, represents pharmaceutical supply procurement by state and local emergency services, though recent solicitation activity under this specific code shows moxonidine itself is not being actively purchased at the state and local level. The City of Tampa's April 2026 Advanced Life Support Medications bid (26P00188) is tagged to this code but solicits four distinct cardiac and vasopressor agents—Labetalol HCl, Epinephrine, Adenosine, and Diltiazem—none of which is moxonidine. The scope of work under this code, as reflected in recent state and local procurement, centers on emergency medical supply contracting by fire and rescue services, with vendors required to meet strict expiration, delivery, quality-assurance, and regulatory compliance standards including OSHA Safety Data Sheets and WCAG 2.2 accessibility documentation. Issuing bodies are municipal purchasing departments acting on behalf of emergency services agencies.

Recent activity in this space is limited; Tampa's April 2026 opportunity, with a $40,000 estimated value and a one-year term plus options to renew, represents a near-term municipal procurement for advanced life support medications but the specific moxonidine commodity does not appear in active state or local solicitation. The Tampa procurement includes a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount capped at $10,000 and requires electronic submission through OpenGov eProcurement by April 8, 2026. The narrow window and Tampa-specific issuance suggest that moxonidine as a standalone commodity code, if pursued, would benefit from direct relationships with municipal fire and rescue procurement offices and readiness to respond to emergency-medical supply RFQs and ITBs with short lead times and firm, all-inclusive pricing.